Can dynamic MR imaging predict response in patients with rectal cancer undergoing cetuximab-based neoadjuvant chemoradiation?

Onkologie

Volumn 32, Issue 3, 2009, Pages 86-93

  Dinter, Dietmar J ^a,d,h   Horisberger, Karoline ^b   Zechmann, Christian ^a,f   Wenz, Frederik ^c,d   Brade, Joachim ^d   Willeke, Frank ^b,g   Neff, K Wolfgang ^a   Schoenberg, Stefan O ^a   Hofheinz, Ralf Dieter ^d,e  

^a Institut fur Klinische Radiologie und Nuklearmedizin   (Germany)

^b Chirurgische Klinik   (Germany)

^c Klinik für Strahlentherapie und Radioonkologie   (Germany)

^d Interdisziplinäres Tumorzentrum Mannheim ^*  (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g St Marien Krankenhaus Siegen gem GmbH   (Germany)

^h UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cetuximab; Dynamic MR imaging; Neoadjuvant radiochemotherapy; Rectal cancer; Therapy response

Indexed keywords

CAPECITABINE; CETUXIMAB; IRINOTECAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; RECTUM CANCER; TREATMENT RESPONSE; TUMOR REGRESSION; TUMOR VOLUME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RADIOTHERAPY, CONFORMAL; RECTAL NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 63849282770     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000194950     Document Type: Article

References (43)

1. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740.
2. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, van Krieken JH, Leer JW, van de Velde CJ: Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001;345:638-646.
3. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
4. Heriot AG, Grundy A, Kumar D: Preoperative staging of rectal carcinoma. Br J Surg 1999;86:17-28.
5. Beets-Tan RG, Beets GL: Rectal cancer: review with emphasis on MR imaging. Radiology 2004;232:335-346.
6. Beets-Tan RG, Beets GL, Vliegen RF, Kessels AG, Van Boven H, De Bruine A, von Meyenfeldt MF, Baeten CG, van Engelshoven JM: Accuracy of magnetic resonance imaging in prediction of tumour-free resection margin in rectal cancer surgery. Lancet 2001;357:497-504.
7. Brown G, Davies S, Williams GT, Bourne MW, Newcombe RG, Radcliffe AG, Blethyn J, Dallimore NS, Rees BI, Phillips CJ, Maughan TS: Effectiveness of preoperative staging in rectal cancer: Digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? Br J Cancer 2004;91:23-29.
8. Brown G, Radcliffe AG, Newcombe RG, Dallimore NS, Bourne MW, Williams GT: Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging. Br J Surg 2003;90:355-364.
9. Martling A, Holm T, Bremmer S, Lindholm J, Cedermark B, Blomqvist L: Prognostic value of preoperative magnetic resonance imaging of the pelvis in rectal cancer. Br J Surg 2003;90:1422-1428.
10. Torkzad MR, Blomqvist L: The mesorectum: morphometry assessment with magnetic resonance imaging. Eur Radiol 2005;15:1184-1191.
11. Torkzad MR, Lindholm J, Martling A, Cedermark B, Glimelius B, Blomqvist L: Mri after preoperative radiotherapy for rectal cancer; correlation with histopathology and the role of volumetry. Eur Radiol 2007;17:1566-1573.
12. Birbeck KF, Macklin CP, Tiffin NJ, Parsons W, Dixon MF, Mapstone NP, Abbott CR, Scott N, Finan PJ, Johnston D, Quirke P: Rates of circumferential resection margin involvement vary between surgeons and predict outcomes in rectal cancer surgery. Ann Surg 2002;235:449-457.
13. Glynne-Jones R, Mawdsley S, Novell JR: The clinical significance of the circumferential resection margin following preoperative pelvic chemo-radiotherapy in rectal cancer: why we need a common language. Colorectal Dis 2006;8:800-807.
14. Mawdsley S, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, Ashford R, Harrison RA, Osborne M, Livingstone JI, MacDonald P, Mitchell IC, Meyrick-Thomas J, Northover JM, Windsor A, Novell R, Wallace M: Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival? Int J Radiat Oncol Biol Phys 2005;63:745-752.
15. Quirke P: Training and quality assurance for rectal cancer: 20 years of data is enough. Lancet Oncol 2003;4:695-702.
16. Wolberink SV, Beets-Tan RG, Nagtegaal ID, Wiggers T: Preoperative assessment of the circumferential margin in rectal cancer is more informative in treatment planning than the t stage. Tech Coloproctol 2006;10:171-176.
17. Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pelegrin A, Dubois JB, Thezenas S: Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 2005;5:62.
18. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Hoff PM, Eng C, Wolff RA, Janjan NA, Delclos ME, Krishnan S, Levy LB, Ellis LM, Crane CH: Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 2006;29:219-224.
19. Das P, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Wolff RA, Eng C, Krishnan S, Janjan NA, Crane CH: Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. Cancer 2007; 109:1750-1755.
20. Park YA, Sohn SK, Seong J, Baik SH, Lee KY, Kim NK, Cho CW: Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. J Surg Oncol 2006;93:145-150.
21. Chen CC, Lee RC, Lin JK, Wang LW, Yang SH: How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy? Dis Colon Rectum 2005;48:722-728.
22. Hoffmann KT, Rau B, Wust P, Stroszczynski C, Hunerbein M, Schneider U, Felix R: Restaging of locally advanced carcinoma of the rectum with mr imaging after preoperative radio-chemotherapy plus regional hyperthermia. Strahlenther Onkol 2002; 178:386-392.
23. Kuo LJ, Chern MC, Tsou MH, Liu MC, Jian JJ, Chen CM, Chung YL, Fang WT: Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 2005;48:23-28.
24. Steinbild S, Arends J, Medinger M, Haring B, Frost A, Drevs J, Unger C, Strecker R, Hennig J, Mross K: Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase ii study. Onkologie 2007;30:629-635.
25. de Lussanet QG, Backes WH, Griffioen AW, Padhani AR, Baeten CI, van Baardwijk A, Lambin P, Beets GL, van Engelshoven JM, Beets-Tan RG: Dynamic contrast-enhanced magnetic resonance imaging of radiation therapy-induced microcirculation changes in rectal cancer. Int J Radiat Oncol Biol Phys 2005;63:1309-1315.
26. Dzik-Jurasz A, Domenig C, George M, Wolber J, Padhani A, Brown G, Doran S: Diffusion mri for prediction of response of rectal cancer to chemoradiation. Lancet 2002;360:307-308.
27. George ML, Dzik-Jurasz AS, Padhani AR, Brown G, Tait DM, Eccles SA, Swift RI: Non-invasive methods of assessing angiogenesis and their value in predicting response to treatment in colorectal cancer. BrJ Surg 2001;88:1628-1636.
28. Hein PA, Kremser C, Judmaier W, Griebel J, Rudisch A, Pfeiffer KP, Hug EB, Lukas P, DeVries AF: (Diffusion-weighted MRI - a new parameter for advanced rectal carcinoma?). Rofo 2003;175:381-386.
29. Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Strubel P, Erben P, Woernle C, Dinter D, Kahler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren): Cetuximab in combination with capecitabine, irinotecan and radiotherapy for patients with locally advanced rectal cancer: results of a phase II MARGIT trial. Int J Radiat Oncol Biol Phys 2009; Epub ahead of print.
30. Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kahler G, Dinter D, Grobholz R, Heeger S, Post S, Hochhaus A, Willeke F: Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer. Int J Radiat Oncol Biol Phys 2006;66:1384-1390.
31. Compton CC: Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: A basis for checklists. Cancer committee. Arch Pathol Lab Med 2000;124:1016-1025.
32. Noworolski SM, Henry RG, Vigneron DB, Kurhanewicz J: Dynamic contrast-enhanced mri in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3d MRSI. Magn Reson Med 2005;53:249-255.
33. Rao C: Linear Statistical Inference and its Application, 2nd ed. New York, Wiley, 1973.
34. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005;23:8688-8696.
35. Roh M, Colangelo S, Wieand S, O'Connell M, Petrelli N, Smith R, Mamounas E, Hyams D, Wolmark N: Response to preoperative multimodality therapy predicts survival in patients with carcinoma of the rectum. ASCO Ann Meet Proc (Post-Meeting Edition) J Clin Oncol 2004;22:3505.
36. Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, Kahler G, Post S, Hofheinz RD: A phase ii study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (caplriRT) as neoadjuvant treatment of locally advanced rectal cancer. BrJ Cancer 2007;96:912-917.
37. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majo J, Benavente S, Armengol M, de Torres I: The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74:101-108.
38. Bipat S, Glas AS, Slors FJ, Zwinderman AH, Bossuyt PM, Stoker J: Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - a meta-analysis. Radiology 2004;232:773-783.
39. Kim NK, Baik SH, Min BS, Pyo HR, Choi YJ, Kim H, Seong J, Keum KC, Rha SY, Chung HC: A comparative study of volumetric analysis, histopathologic downstaging, and tumor regression grade in evaluating tumor response in locally advanced rectal cancer following preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2007;67:204-210.
40. Kim YH, Kim DY, Kim TH, Jung KH, Chang HJ, Jeong SY, Sohn DK, Choi HS, Ahn JB, Kim DH, Lim SB, Lee JS, Park JG: Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys 2005;62:761-768.
41. Atkin G, Taylor NJ, Daley FM, Stirling JJ, Richman P, Glynne-Jones R, d'Arcy JA, Collins DJ, Padhani AR: Dynamic contrast-enhanced magnetic resonance imaging is a poor measure of rectal cancer angiogenesis. Br J Surg 2006;93:992-1000.
42. DeVries A, Griebel J, Judmaier W, Kremser C, Rieger M, Gneiting T, Lukas P: (Perfusion-index values evaluated by dynamic magnetic resonance imaging in advanced rectal carcinoma. A new predictor of response to preoperative radiochemotherapy?). Strahlenther Onkol 2000;176:567-572.
43. Mayr NA, Yuh WT, Magnotta VA, Ehrhardt JC, Wheeler JA, Sorosky JI, Davis CS, Wen BC, Martin DD, Pelsang RE, Buller RE, Oberley LW, Mellenberg DE, Hussey DH: Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: a new noninvasive predictive assay. Int J Radiat Oncol Biol Phys 1996;36:623-633.